Catherine Ivy sat down with Devin Thorpe's Your Mark On The World to discuss her personal fight with glioblastoma and how she hopes to shake up the research process with her investment in the Ivy Center's Phase 0 clinical trials.
Ivy Brain Tumor Center And BridgeBio Subsidiary QED Therapeutics Announce Collaboration To Advance Cancer Research And Treatment Options
The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment of glioblastoma (GBM).
Social Impact Heroes: “Why Catherine Ivy and the Ivy Foundation have contributed over $91 million to accelerate drug and treatment discovery for brain cancer”
Catherine Ivy was recently interviewed for Authority Magazine's latest "Social Impact Heroes" series where she opened up about her 14-year journey to accelerate drug discovery for brain tumor patients, a recent success story from the Ivy Center's Phase 0 clinical trials program, and what our community, society and politicians can do to help address the unmet needs of patients battling aggressive brain tumors.
Ivy Brain Tumor Center And Salarius Pharmaceuticals Launch Collaborative Partnership To Develop New Cancer Treatment For Glioblastoma
The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat, for the treatment of glioblastoma.
The Ivy Brain Tumor Center at the Barrow Neurological Institute recently completed a Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali) for the treatment of recurrent glioblastoma. The Ivy recently received $50 million to combat brain cancer. This new drug cocktail represents one of the potential weapons in humankind’s war against this killer disease.
Barrow Neurological Foundation led a fundraising effort that raised more than $539,000 for brain cancer research at the Ivy Brain Tumor Center on the first ever Glioblastoma Awareness Day, July 17, 2019.
The Ivy Brain Tumor Center at the Barrow Neurological Institute has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali®) for the treatment of recurrent glioblastoma.
Newsweek's cover story examines the rising success of precision medicine to fight once-untreatable tumors and highlights our efforts in using this method to fight glioblastoma where speed and personalization are key.
The Ivy Brain Tumor’s goal is to try to speed advances into the clinic by testing potential therapies on tumor samples taken from patients who are currently battling glioblastoma—an approach its researchers hope will shed some light on the potential of Karyopharm’s new drug in treating the disease.
Ivy Brain Tumor Center And Karyopharm Therapeutics Collaborate To Develop Tissue-Based Clinical Trial For Brain Cancer
The Ivy Brain Tumor Center at the Barrow Neurological Institute has announced a partnership with Karyopharm Therapeutics (Nasdaq:KPTI) to accelerate the treatment of brain cancer.